SCHEMBL9921977

SCHEMBL9921977

CN1C(=O)CSc2ccc(Nc3c(C(N)=O)nnc4[nH]ccc34)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
POLB P06746 3/20 0.47
MAPK1 P28482 7/20 0.46
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
MAPT P10636 12/20 0.46
HTT P42858 4/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
USP2 O75604 4/20 0.46
NPC1 O15118 2/20 0.46
LMNA P02545 2/20 0.46
RAB9A P51151 2/20 0.46
HBB P68871 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
OPRM1 P35372 1/20 0.45
OPRD1 P41143 1/20 0.45
TP53 P04637 2/20 0.44
TSHR P16473 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
ALOX15 P16050 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9918556 0.90 ALDH1A1 (0.36) ALDH1A1POLBMAPK1MEN1KMT2A
SCHEMBL9921975 0.85 ALDH1A1 (0.34) ALDH1A1POLBMAPK1MEN1KMT2A
SCHEMBL9918562 0.81 SYK (0.47) POLBTSHRL3MBTL1
SCHEMBL9918558 0.80 HTT (0.41) ALDH1A1POLBMAPK1MEN1KMT2A
SCHEMBL9918561 0.79 JAK2 (0.32)
SCHEMBL9923296 0.70 JAK2 (0.47) ALDH1A1POLBMAPK1MEN1KMT2A
SCHEMBL12833307 0.70 LRRK2 (0.43) MAPT
SCHEMBL9921770 0.70 SMN1; SMN2 (0.42) ALDH1A1POLBMAPK1MEN1KMT2A
SCHEMBL9918545 0.69 CSF1R (0.46) ALDH1A1POLBMEN1KMT2AMAPT
SCHEMBL5912909 0.69 LMNA (0.78) ALDH1A1POLBMAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149662-A1 Heterocyclic Compounds as Janus Kinase Inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149662-A1 Heterocyclic Compounds as Janus Kinase Inhibitors JAK2, JAK1, JAK3 ALDH1A1 1507/4885POLB 3280/4885MAPK1 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.